ARK Investment Management LLC acquired a new stake in MediWound Ltd. (NASDAQ:MDWD - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 99,994 shares of the biopharmaceutical company's stock, valued at approximately $1,806,000. ARK Investment Management LLC owned 0.93% of MediWound as of its most recent filing with the SEC.
Several other institutional investors have also added to or reduced their stakes in the business. Rhumbline Advisers purchased a new stake in MediWound during the 2nd quarter worth about $131,000. Bank of New York Mellon Corp bought a new position in shares of MediWound in the second quarter valued at approximately $342,000. Rosalind Advisors Inc. grew its stake in MediWound by 5.7% during the second quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company's stock valued at $7,969,000 after acquiring an additional 27,500 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in MediWound during the 1st quarter worth approximately $427,000. 46.83% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
MDWD has been the topic of several research analyst reports. Maxim Group upped their price target on shares of MediWound from $25.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, July 16th. StockNews.com raised MediWound to a "sell" rating in a report on Monday, August 5th. Finally, HC Wainwright reissued a "buy" rating and set a $28.00 price objective on shares of MediWound in a report on Friday, October 11th.
Get Our Latest Research Report on MediWound
MediWound Stock Up 2.9 %
NASDAQ:MDWD traded up $0.50 during midday trading on Friday, hitting $17.29. The company had a trading volume of 37,719 shares, compared to its average volume of 35,104. The stock's fifty day moving average price is $17.36 and its 200-day moving average price is $17.54. MediWound Ltd. has a 52-week low of $7.45 and a 52-week high of $24.00. The company has a market capitalization of $186.51 million, a PE ratio of -8.00 and a beta of 0.83.
MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.26). The firm had revenue of $5.06 million during the quarter, compared to analysts' expectations of $5.07 million. MediWound had a negative return on equity of 52.49% and a negative net margin of 99.17%. As a group, research analysts forecast that MediWound Ltd. will post -2.03 earnings per share for the current year.
About MediWound
(
Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Read More
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
